A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
Inclusion Criteria:
Exclusion Criteria:
Have a prior or planned surgical treatment for obesity,
Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma
Have poorly controlled hypertension
Have any of the following cardiovascular conditions within 3 months prior to screening:
Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
Have renal impairment
Have a history of symptomatic gallbladder disease within the past 2 years
Have signs and symptoms of any liver disease
Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
Have a history of acute or chronic pancreatitis
Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Luoyang Shi, Henan 471003, China
Kamakura-shi, Kanagawa 247-0056, Japan
Suita-shi, Osaka 565-0853, Japan
Chuo-ku, Tokyo 103-0002, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 104-0031, Japan